GlassScriptPhysician profile
Jeremy N Young
NPI 1730385501
$6,940.57
in general payments reported to CMS, 2019-2025
28 companies · $1,062 in 2025
The $1,062 reported for 2025 was more than what 95% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $997 · 2020: $532 · 2021: $1,162 · 2022: $1,191 · 2023: $863 · 2024: $1,134 · 2025: $1,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,058.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,214.51 | 2019-2025 | |
| Abbvie INC. | $856.96 | 2021-2025 | Dalvance, Avycaz, Teflaro |
| Novartis Pharmaceuticals Corporation | $698.06 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $603.77 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $554.69 | 2019-2025 | Zerbaxa, Dificid, Verquvo |
| Janssen Pharmaceuticals, INC | $460.88 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $418.95 | 2019-2024 | Andexxa, Lokelma, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $391.90 | 2020-2025 | Xifaxan |
| Allergan, INC. | $248.12 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $234.40 | 2019-2025 | Ultomiris |
| Gilead Sciences, INC. | $209.31 | 2021-2024 | Veklury |
| E.R. Squibb & Sons, L.L.C. | $191.08 | 2019-2025 | Eliquis |
| Boston Scientific Corporation | $132.98 | 2020-2024 | Watchman Flx |
| Otsuka America Pharmaceutical, INC. | $103.91 | 2019 | |
| Sk Life Science, INC. | $99.91 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $96.09 | 2022-2023 | Nuzyra |
| Novo Nordisk INC | $78.07 | 2019-2024 | Rybelsus, Ozempic |
| Sunovion Pharmaceuticals INC. | $63.70 | 2019 | |
| Lundbeck LLC | $47.36 | 2019 | |
| Smith+Nephew, INC. | $38.77 | 2025 | Collagenase Santyl |
| Philips North America LLC | $33.75 | 2021-2023 | |
| Electromed, INC. | $29.97 | 2023 | Smartvest |
| Cvrx, INC. | $29.72 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.13 | 2025 | Lifevest |
| Abbott Laboratories | $23.47 | 2024 | Mitraclip |
| Melinta Therapeutics, LLC | $21.31 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.20 | 2024 | |
| Shire North American Group INC | $13.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.